

Thomas B Brunner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5640590/publications.pdf>

Version: 2024-02-01

70
papers

2,559
citations

201385

27
h-index

197535

49
g-index

82
all docs

82
docs citations

82
times ranked

4021
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 100-112.	1.9	9
2	125Âyears of head and neck radiotherapy: could organ-sparing radiotherapy of larynx cancer have prevented World WarÂI?. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 325.	1.0	0
3	FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 27-38.	1.0	11
4	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 154, 60-69.	0.3	36
5	Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic) Tj ETQq1 1 0.784314 rgBTz/Overlodk 10 Tf 50	0.784314	10
6	Natural Meros Sesquiterpenes Activate the DNA Damage Response via DNA Strand Break Formation and Trigger Apoptotic Cell Death in p53-Wild-Type and Mutant Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3282.	1.7	7
7	Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145. <i>Radiation Oncology</i> , 2021, 16, 137.	1.2	0
8	ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies. <i>Radiotherapy and Oncology</i> , 2021, 164, 92-97.	0.3	4
9	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. <i>Cancer Treatment Reviews</i> , 2021, 99, 102208.	3.4	4
10	Radiation-induced damage in the upper gastrointestinal tract: clinical presentation, diagnostic tests and treatment options. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101711.	1.0	9
11	Bratislava Statement: consensus recommendations for improving pancreatic cancer care. <i>ESMO Open</i> , 2020, 5, e001051.	2.0	12
12	Heme oxygenase 1 protects human colonocytes against ROS formation, oxidative DNA damage and cytotoxicity induced by heme iron, but not inorganic iron. <i>Cell Death and Disease</i> , 2020, 11, 787.	2.7	49
13	Interstitial Brachytherapy for Limited (<4 cm) and Large (â%¥4 cm) Hepatic Metastases from Rare and Less Common Cancers. <i>Anticancer Research</i> , 2020, 40, 4281-4289.	0.5	4
14	The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 604387.	1.3	14
15	Phase II HEPANOVA trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS603-TPS603.	0.8	1
16	Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. <i>Brachytherapy</i> , 2019, 18, 823-828.	0.2	23
17	Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. <i>Radiotherapy and Oncology</i> , 2019, 132, 42-47.	0.3	44
18	First report on extended distance between tumor lesion and adjacent organs at risk using interventionally applied balloon catheters: a simple procedure to optimize clinical target volume covering effective isodose in interstitial high-dose-rate brachytherapy of liver malignomas. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 152-161.	0.4	12

#	ARTICLE	IF	CITATIONS
19	Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 199-206.	1.0	19
20	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	4.2	31
21	ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 193-198.	1.0	143
22	Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection. <i>Radiation Oncology</i> , 2018, 13, 28.	1.2	11
23	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. <i>Future Oncology</i> , 2018, 14, 751-769.	1.1	7
24	Correspondence on Rajyaguru et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2561-2562.	0.8	2
25	Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. <i>BMC Cancer</i> , 2018, 18, 807.	1.1	27
26	Alternate Fractionation for Hepatic Tumors. <i>Medical Radiology</i> , 2017, , 173-201.	0.0	0
27	Pancreatic stellate cells in pancreatic cancer: In focus. <i>Pancreatology</i> , 2017, 17, 514-522.	0.5	37
28	ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 306-311.	0.3	43
29	Chemoradiotherapy, the backbone of radiotherapy in gastrointestinal oncology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 511-513.	1.0	2
30	The rationale of combined radiotherapy and chemotherapy – Joint action of Castor and Pollux. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 515-528.	1.0	19
31	Pancreatic cancer chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 617-628.	1.0	11
32	Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 565-580.	1.0	14
33	Radiation therapy in cholangiocellular carcinomas. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 593-602.	1.0	16
34	Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 875-885.	1.0	19
35	Simultaneous integrated protection. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 886-894.	1.0	43
36	The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. <i>Radiotherapy and Oncology</i> , 2016, 119, 300-305.	0.3	9

#	ARTICLE	IF	CITATIONS
37	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 14-27.	0.5	81
38	SBRT in pancreatic cancer: What is the therapeutic window?. <i>Radiotherapy and Oncology</i> , 2015, 114, 109-116.	0.3	85
39	Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer – A systematic review. <i>Radiotherapy and Oncology</i> , 2015, 114, 117-121.	0.3	73
40	Neoadjuvante Radiochemotherapie mit Gemcitabin/Cisplatin gefolgt von Resektion versus primärer Resektion bei resektablem Pankreaskopfkarcinom. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 7-16.	1.0	255
41	Radiotherapy for SMAD4-negative musculoskeletal lesions from pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 67-72.	1.0	0
42	Endobiliary Stent Position Changes during External-beam Radiotherapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2015, 46, 57-64.	0.2	3
43	IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. <i>Oncolmmunology</i> , 2015, 4, e1027473.	2.1	71
44	Impact of 4D-18FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study. <i>Radiotherapy and Oncology</i> , 2015, 115, 335-341.	0.3	37
45	Stereotactic Body Radiation Therapy for Liver Cancer: Effective Therapy With Minimal Impact on Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 26-28.	0.4	5
46	Influence of IP-10/CXCL10 induction in human pancreatic cancer stroma on lymphocytes recruitment and correlation with survival.. <i>Journal of Clinical Oncology</i> , 2015, 33, 290-290.	0.8	1
47	ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC) – Mechanism and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15279-e15279.	0.8	0
48	IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. <i>Oncotarget</i> , 2014, 5, 11064-11080.	0.8	103
49	Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells. <i>Radiotherapy and Oncology</i> , 2014, 111, 243-251.	0.3	68
50	The stromal compartments in pancreatic cancer: Are there any therapeutic targets?. <i>Cancer Letters</i> , 2014, 343, 147-155.	3.2	155
51	Stereotactic body radiotherapy for liver tumors. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 872-881.	1.0	99
52	A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 200-206.	0.3	13
53	Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?. <i>Current Oncology Reports</i> , 2013, 15, 162-169.	1.8	11
54	Comparison of four target volume definitions for pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 407-416.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Cancer Stem Cells as a Predictive Factor in Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2012, 22, 151-174.	1.0	83
56	Pancreatic Stellate Cells Radioprotect Pancreatic Cancer Cells through β 21-Integrin Signaling. <i>Cancer Research</i> , 2011, 71, 3453-3458.	0.4	185
57	Radiotherapy and Chemotherapy as Therapeutic Strategies in Extrahepatic Biliary Duct Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 672-680.	1.0	26
58	The role of radiotherapy in multimodal treatment of pancreatic carcinoma. <i>Radiation Oncology</i> , 2010, 5, 64.	1.2	44
59	Downstaging of Pancreatic Carcinoma after Neoadjuvant Chemoradiation. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 557-566.	1.0	38
60	Radiation Response of Cancer Stem-Like Cells From Established Human Cell Lines After Sorting for Surface Markers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1216-1225.	0.4	38
61	Esophageal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 15-22.	1.0	22
62	Radiotherapy in Pancreatic Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 557-564.	1.0	14
63	Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2699-2706.	0.8	146
64	Molecular verification of stereotactic radiotherapy in rats using ATMpS1981 immunofluorescence. <i>Radiotherapy and Oncology</i> , 2006, 79, 109-114.	0.3	7
65	Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning. <i>Radiotherapy and Oncology</i> , 2006, 81, 190-195.	0.3	8
66	Maintenance Chemotherapy after Chemoradiation Improves Survival of Patients with Locally Advanced Pancreatic Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 210-215.	1.0	14
67	Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1021-1029.	0.4	45
68	Chemoradiation May Prolong Survival of Patients with Non-Bulky Unresectable Extrahepatic Biliary Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 751-757.	1.0	38
69	Radiation Sensitization by Inhibition of Activated Ras. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 731-740.	1.0	25
70	Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 144-153.	0.4	51